<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="ago, the recommended therapy for HCV treatment consisted of pegylated-interferon" exact="alpha" post="plus ribavirin, a therapy with important side effects. This"/>
 <result pre="and SCD patients due to the hemolytic anemia induced by" exact="ribavirin" post="causing an increase in the number of blood transfusions."/>
 <result pre="therapy available for HCV treatment was pegylated-interferon (PEG-IFN) alpha, plus" exact="ribavirin" post="(RBV) with an administration of about 24 weeks (genotypes"/>
 <result pre="SCD patients and the use has been severely reduced because" exact="ribavirin" post="(RBV) proved to cause hemolytic anemia and to increase"/>
 <result pre="consisted of the combination with PEG-INF plus RBV. In 2013," exact="simeprevir" post="and sofosbuvir were introduced. These two drugs were proposed"/>
 <result pre="the combination with PEG-INF plus RBV. In 2013, simeprevir and" exact="sofosbuvir" post="were introduced. These two drugs were proposed to treat"/>
 <result pre="of the iron overload an iron chelation therapy was administered:" exact="deferoxamine" post="(DFO) in 29% of patients, deferiprone (DFP) in 13%"/>
 <result pre="of the patients treated with DAAs and comparison of serum" exact="alanine" post="aminotransferase (ALT), liver iron concentration (LIC), and serum ferritin"/>
 <result pre="therapy, n (%) Sofosbivir + Ledipasvir 14 (41%) Sofosbivir +" exact="Daclatasvir" post="4 (12%) Sofosbuvir + Velpatasvir 9 (26%) Simeprevir +"/>
 <result pre="Sofosbivir + Ledipasvir 14 (41%) Sofosbivir + Daclatasvir 4 (12%)" exact="Sofosbuvir" post="+ Velpatasvir 9 (26%) Simeprevir + Sofosbivir 2 (6%)"/>
 <result pre="Ledipasvir 14 (41%) Sofosbivir + Daclatasvir 4 (12%) Sofosbuvir +" exact="Velpatasvir" post="9 (26%) Simeprevir + Sofosbivir 2 (6%) Sofosbivir 2"/>
 <result pre="Sofosbivir + Daclatasvir 4 (12%) Sofosbuvir + Velpatasvir 9 (26%)" exact="Simeprevir" post="+ Sofosbivir 2 (6%) Sofosbivir 2 (6%) Elbasvir +"/>
 <result pre="(Table 1) suggested a significant reduction (p = 0.018) in" exact="alanine" post="aminotransferase levels from 44.0 ± 30.1 IU/L at baseline"/>
 <result pre="conflict of interest. References References AfdhalN.ZeuzemS.KwoP.ChojkierM.GitlinN.PuotiM.et al.. (2014). Ledipasvir and" exact="sofosbuvir" post="for untreated HCV genotype 1 infection. N. Engl. J."/>
 <result pre="AminizadehE.AlavianmS. M.Akbari SarmA.Ebrahimi DaryaniN.BehnavaB. (2016). Safety and efficacy of adding" exact="ribavirin" post="to interferon or peginterferon in treatment of hepatitis C"/>
 <result pre="Di MarcoV.D'AmbrosioR.BronteaF.SaraccoG.LanzaA. G.Forniet al.. (2016). Dual therapy with peg-interferon and" exact="ribavirin" post="in thalassemia major patients with chronic HCV infection: is"/>
 <result pre="al.. (2008). Safety and efficacy of pegylated interferon alpha-2a and" exact="ribavirin" post="for the treatment of hepatitis C in patients with"/>
 <result pre="(2005). Efficacy and tolerability of peginterferon alpha-2a with or without" exact="ribavirin" post="in thalassaemia major patients with chronic hepathitis C virus"/>
 <result pre="79–85.e2. 10.1016/j.jpeds.2017.06.03528735981 LiC. K.ChanP. K.LingS. C.HaS. Y. (2002). Interferon and" exact="ribavirin" post="as frontline treatment for chronic hepatitis C infection in"/>
 <result pre="Talanta174, 673–678. 10.1016/j.talanta.2017.06.04428738640 MehtaR.KabrawalaM.NandwaniS.DesaiP.BhayaniV.Patelet al.. (2018). Safety and efficacy of" exact="sofosbuvir" post="and daclatasvir for hepatitis C virus infection in patients"/>
 <result pre="10.1016/j.talanta.2017.06.04428738640 MehtaR.KabrawalaM.NandwaniS.DesaiP.BhayaniV.Patelet al.. (2018). Safety and efficacy of sofosbuvir and" exact="daclatasvir" post="for hepatitis C virus infection in patients with β-thalassemia"/>
</results>
